|
Market Closed -
Nasdaq
21:00:00 02/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 10.50 USD | -6.75% |
|
-10.79% | -33.04% |
| 10-01 | Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102 | CI |
| 10-01 | Monte Rosa Therapeutics, Inc. - Special Call |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 895.8 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | -12.27% | - | - |
| Enterprise Value (EV) | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 895.8 | 895.8 | 895.8 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | -12.27% | 0% | 0% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -7.1x | -5.34x | -6.06x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | - | - | - |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -0.2x | 0.5x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 13.3x | 16.6x | 8.79x |
| EV / Revenue | - | - | - | 0x | 0x | 13.3x | 16.6x | 8.79x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -5.29x | -4.02x | -4.31x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -15.2x | -12.8x | 28.6x |
| FCF Yield | -7.28% | -28.6% | -22.2% | 8.91% | -2.69% | -6.6% | -7.81% | 3.49% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.479 | -1.966 | -1.734 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 67.43 | 53.93 | 101.9 |
| EBITDA | -70.75 | -108.6 | -137.1 | -72.99 | - | - | - | - |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -169.2 | -222.7 | -207.9 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -149.5 | -207.3 | -196.5 |
| Net Debt | -346.1 | -262.8 | -232.4 | -372.1 | - | - | - | - |
| Reference price 2 | 20.42 | 7.61 | 5.65 | 6.94 | 15.68 | 10.50 | 10.50 | 10.50 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 85,313 | - | - |
| Announcement Date | 29/03/22 | 16/03/23 | 14/03/24 | 20/03/25 | 17/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.1x | - | - | - | 896M | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 18.17x | 31.37x | 12.47x | 0.31% | 39.14B | |
| Weighted average by Cap. | 22.20x | 32.04x | 13.55x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
